K65R, TAMs and tenofovir

AIDS Reviews

Volumn 6, Issue 1, 2004, Pages 22-33

  Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

HIV; Resistance; Tenofovir

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PLACEBO; PRODRUG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG METABOLISM; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PHENOTYPE; REVIEW; VIRUS MUTATION; VIRUS REPLICATION;

ADENINE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 2342661255     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry & Chemotherapy 1997;8:1-23.
2. Arimilli M, Kim C, Bischofberger N. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antiviral Chemistry & Chemotherapy 1997;8:557-64.
3. Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9(2-phosphonylmethoxypropyl) adenine in mice. Antimicrob Agents Chemother 1998;42:1568-73.
4. Balzarini J, Holy A, Jindrich J, et al. Differential anti-herpesvirus and anti-retrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo anti-retrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2, 6-diaminopurine. Antimicrob Agents Chemother 1993;37:332-8.
5. Robbins B, Srinivas R, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998;42:612-7.
6. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R Jr, Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodefiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses 2001;17:1167-73.
7. Yokota T, Konno K, Shigeta S, Holy A, Balzini J, De Clerq E. Inhibitory effects of acyclic nucleoside phosphonate analogues of hepatitis B virus DNA synthesis in HB611 cells. Antiviral Chemistry & Chemotherapy 1994;5:557-63.
8. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1997;337:853-60.
9. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr Hum Retrovirol 2001;26:10-24.
10. Sarafianos S, Das K, Clark A, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids. Proc Natl Acad Sci USA 1999;96:10027-32.
11. Meyer P, Matsuura S, So A, Scott W. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998;95:13471-6.
12. Meyer P. Matsuura S, Schinazi R, So A, Scott W. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse trancriptase in the presence of physiological concentrations of 2′-deoynucleoside triphosphates. Antimicrob Agents Chemoter 2000;44:3465-72.
13. Skowron G, Whitcomb J, Wesley M, et al. Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V. Antivir Ther 1999;4:55-6[abstract 81].
14. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immumodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997;41:1094-8.
15. Opravil M, Yerly S, Staszewski S, Stone C, Ait-Khaled M, Perrin L. Prior treatment with mono or dual NRTIs before HAART as predictor of virological failure in simplified abacavir-based triple NRTI regimens: results from the Simplified Maintenance Trial (SMT) and CNA30017. Antivir Ther 2000;5:95-6 [abstract 120].
16. Lanier E, Hellmann N, Scott J, et al. Determination of a clinically relevant phenotypic resistance 'cut-off for abacavir using the PhenoSense assay. In: Program and abstracts of the 8th Conference on Retroviruses and Oppurtunistic Infections. Chicago, Ill, USA 2001 (abstract).
17. Shirasaka T, Kavlick M, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-402.
18. Larder B, Bloor S, Kemp S, et al. A family of insertion mutations between codons 67 and 70 of human immunodefienciency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999;43:1961-7.
19. Wainberg M, Miller M, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999;4:87-94.
20. Srinivas R, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isoproploxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998;42:1484-7.
21. Miller M, Anton K, Mulato A, Lamy P, Cherrington J. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999;179:92-100.
22. Miller M, Margot N, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotheraphy. Toronto, ON, Canada 2000.
23. Gu Z, Gao Q, Fang H, et al. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxycytidine and 2′,3′ -dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38:275-81.
24. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. The Journal of Infectious Diseases 1997;176:899-903.
25. García-Lerma J, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-93.
26. Margot N, Isaacson E, McGowan I, Cheng A, Schooley R, Miller M. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002;16:1227-35.
27. Schooley R, Ruane P, Myers R, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63.
28. Squires K, Pozniak A, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med 2003;139:313-21.
29. Barditch-Crovo P, Deeks S, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
30. Miller M, Margot N, Naeger L, Coakley D, Cheng A. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF therapy: baseline and week 24 genotypic analyses of study 907 (poster). In:Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, III 2001.
31. Miller M, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of treament response to tenofovir disoproxil fumarate in antiretroviral-experienced patients. J Infect Dis 2003;189:837-46.
32. Miller M, Zhong L, Chen S, Margot N, Wulfsohn M. Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviral-experienced patients. Antivir Ther 2002;7:16.
33. Hanna G, Johnson V, Kuritzkes D, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000;181:904-11.
34. Yahi N, Tamalet C, Tourres C, Tivoli N, Fantini J. Mutation L210W of HIV-1 reverse trascriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci 2000:507-13.
35. Margot N, Isaacson E, McGowan I, Cheng A, Miller M. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr Hum Retrovirol 2003;33:15-21.
36. Margot N, Johnson A, Cheng A, Coakley D, Miller M. Final 48-week genotypic and phenotypic analyses of study 907: tenofovir DF (TDF) added to stable background regimens [poster abstract]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA 2002.
37. McColl D, Margot N, Cheng A, Miller M. Development of K65R vs thymidine analogue-associated mutations (TAMs) in antiretroviral-treated patients. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK 2002.
38. Staszewski S, Gallant J, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral-naive patients. 96-week preliminary interim results [poster]. In: Program and abstracts of the 10th Conference on Retroviruses and Oppurtunistic Infections. Boston, Mass, USA 2003.
39. Miller M, Margot N, McColl D, Wring T, Coakley D, Cheng A. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF of stavudine in combination with lamivudine and efavirenz. Antivir Ther 2003;8:151 (abstract).
40. Zhang D, Caliendo A, Eron J, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994;38:282-7.
41. Gu Z, Fletcher R, Arts E, Wainberg M, Parniak M. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′ -thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 1994;269:28118-22.
42. White K, Margot N, Wrin T, Petropoulus C, Miller M, Naeger L. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002;46:3437-46.
43. Selmi B, Boretto J, Sarfati S, Guerreiro C, Canard B. Mechanism-based suppression of dideoxynucleotideby K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J Biol Chem 2001;276:48466-72.
44. Arion D, Borkow G, Gu Z, Wainberg M, Parniak M. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J Biol Chem 1996;271:19860-4.
45. Shah F, Curr K, Hamburgh M, et al. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 2000;275:27037-44.
46. Miller M, White K, Petropoulos C, Parkin N. Decreased replication capacity of HIV-1 clinical isolates containing K65R or M184V RT mutations [poster]. In: Program and abstract of the 10th Conference on Retrovirus and Opportunistic Infections. Boston, Mass, USA 2003.
47. Back N, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-9.
48. Deval J, Navarro J, Selmi B, et al. Molecular mechanism for the mutual exclusion of K65Rand L74V substitutions in HIV-1 reverse transcriptase-mediated dideonucleoside resistance. Antivir Ther 2003;8:40 [abstract 35].
49. Deval J, White K, Miller M, et al. Drug resistance and viral fitness at the molecular level: the case of tenofovir. Antivir Ther 2003;8:39 [abstract].
50. Whitcombe J, Paxinos E, Huang W, et al. The presence of nucleoside analogue mutations (NAMS) is highly correlated with reduced susceptibility to all NRTIs [poster]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA 2002.
51. Campbell T, Young R, Johnson S, Lanier E, Kuritzkes D. Antiviral activity of lamivudine in persons infected with HIV-1 that has M184V and multiple thymidine analogue mutations. Antivir Ther 2003;8:156 [abstract].
52. Miller M, McColl D, White K, Parkin N. Genotypic and phenotypic characterization of patient-derived HIV-1 isolates containing the K65R mutation in reverse transcriptase (RT) [poster]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, III, USA 2003.
53. Parkin N, Chappey C, Petropoulos C, Hellman N. HIV-1 reverse transcriptase mutations that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine. Antivir Ther 2003;8:34 [abstract 29].
54. Gonzales M, Wu T, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003;17:791-9.
55. Roge B, Katzenstein T, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003;8:173-82.
56. Winters M, Shafer R, Jellinger R, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997;41:757-62.
57. Miller V, Ait-Khaled M, Stone C, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000;14:163-71.
58. Harrigan P, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J Infect Dis 2000;181:912-20.
59. Ait-Khaled M, Lanier R, Richards N, et al. Zidovudine appears to prevent selection of K65R and L74V mutations normally selected by abacavir mono- or combination therapies not containing zidovudine. Antivir Ther 2002;7:141.
60. Bazmi H, Hammond J, Cavalcanti S, Chu C, Schinazi R, Mellors J. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrb Agents Chemother 2000;44:1783-8.
61. Gulick R, Ribaudo H, Shikuma C, et al. ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. Antivir Ther 2003;8:194-5 [abstract 41].
62. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Antivir Ther 2003;8:195 [abstract 43].
63. Gallant J, Rodríguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS300009 unplanned interim analysis [oral presentation]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Ill, USA 2003.